JP2025507448A - Ｖｗｆ標的化単特異性抗体により血液障害を処置する方法 - Google Patents

Ｖｗｆ標的化単特異性抗体により血液障害を処置する方法 Download PDF

Info

Publication number
JP2025507448A
JP2025507448A JP2024569671A JP2024569671A JP2025507448A JP 2025507448 A JP2025507448 A JP 2025507448A JP 2024569671 A JP2024569671 A JP 2024569671A JP 2024569671 A JP2024569671 A JP 2024569671A JP 2025507448 A JP2025507448 A JP 2025507448A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
identity
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024569671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507448A5 (https=
JPWO2023156409A5 (https=
Inventor
オステルガルド，ヘンリク
エス ガンディー，プラフル
エイチ． フェイバー，ヨハン
レア，キャサリン
セーレンセン，ベニー
Original Assignee
ヒーマブ エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヒーマブ エーピーエス filed Critical ヒーマブ エーピーエス
Publication of JP2025507448A publication Critical patent/JP2025507448A/ja
Publication of JP2025507448A5 publication Critical patent/JP2025507448A5/ja
Publication of JPWO2023156409A5 publication Critical patent/JPWO2023156409A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024569671A 2022-02-15 2023-02-14 Ｖｗｆ標的化単特異性抗体により血液障害を処置する方法 Pending JP2025507448A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263268040P 2022-02-15 2022-02-15
US63/268,040 2022-02-15
US202263269000P 2022-03-08 2022-03-08
US63/269,000 2022-03-08
PCT/EP2023/053681 WO2023156409A1 (en) 2022-02-15 2023-02-14 Methods of treating blood disorders with vwf-targeted monospecific antibodies

Publications (3)

Publication Number Publication Date
JP2025507448A true JP2025507448A (ja) 2025-03-18
JP2025507448A5 JP2025507448A5 (https=) 2026-02-20
JPWO2023156409A5 JPWO2023156409A5 (https=) 2026-02-20

Family

ID=85278579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024569671A Pending JP2025507448A (ja) 2022-02-15 2023-02-14 Ｖｗｆ標的化単特異性抗体により血液障害を処置する方法

Country Status (8)

Country Link
US (1) US20250154283A1 (https=)
EP (1) EP4479435A1 (https=)
JP (1) JP2025507448A (https=)
KR (1) KR20240159860A (https=)
CN (1) CN119032109A (https=)
AU (1) AU2023221511A1 (https=)
CA (1) CA3244108A1 (https=)
WO (1) WO2023156409A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR133583A1 (es) * 2023-08-16 2025-10-15 Hemab Aps Métodos para tratar trastornos de la sangre con anticuerpos monoespecíficos dirigidos a vwf
WO2025174998A1 (en) * 2024-02-13 2025-08-21 Invetx, Inc. Anti-il-31ra antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707139D0 (en) * 2017-05-04 2017-06-21 Imp Innovations Ltd Polypeptides

Also Published As

Publication number Publication date
EP4479435A1 (en) 2024-12-25
WO2023156409A1 (en) 2023-08-24
US20250154283A1 (en) 2025-05-15
KR20240159860A (ko) 2024-11-06
CN119032109A (zh) 2024-11-26
AU2023221511A1 (en) 2024-09-12
CA3244108A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
CA2747519C (en) Anti-fxi antibodies and methods of use
Schiele et al. A specific antidote for dabigatran: functional and structural characterization
Ulrichts et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs
US20190248920A1 (en) Coagulation factor binding proteins and uses thereof
CN105263514A (zh) 抗铁调素抗体及其用途
KR102114506B1 (ko) 트롬빈-결합 항체 분자 및 이의 용도
JP2021535161A (ja) 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
TW201605904A (zh) 治療凝血病變之新穎方法及抗體
CN108289939A (zh) 新型抗人gpvi抗体及其用途
US20250154283A1 (en) Methods of treating blood disorders with vwf-targeted monospecific antibodies
JP2022529036A (ja) 二重特異性抗体
US11542329B2 (en) Antibodies targeting Glycoprotein VI
TWI910161B (zh) 蛋白質s抗體、其製造方法及其用途
AU2022210221A1 (en) Immunomodulatory antibodies and uses thereof
TW201529602A (zh) 對抗抗凝血酶β之單株抗體
JP2021527424A (ja) 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用
US20240084029A1 (en) Use of immunomodulatory antibodies to treat fibrotic diseases
TW202509085A (zh) 以靶向ｖｗｆ之單專一性抗體治療血液病症的方法
JP6445440B2 (ja) 抗プロテインｃ抗体による出血性疾患の治療
HK40118720A (zh) 用靶向vwf的单特异性抗体治疗血液病症的方法
CN118414168A (zh) 因子xi a2结构域结合抗体和其使用方法
EA048026B1 (ru) Ингибиторы калликреина плазмы и их применения для лечения приступа наследственного ангионевротического отека
CN117062835A (zh) 免疫调节性抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260210